ArticleAddiction & health2025
Therapeutic Potential of Black Seed and Opium Poppy Oils in Mitigating Morphine Withdrawal Syndrome in an Animal Model.
Article in Addiction & health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dependence and withdrawal syndrome caused by opioids are the most important and unambiguous factors in the clinical use of narcotic painkillers. Some evidence indicates the beneficial effects of herbal fragments in attenuating this complication. In the current study, the impact of black seed oil (BSO) and opium poppy oil (OPO) was investigated on the symptoms of morphine withdrawal syndrome in mice. Methods: For three days, morphine was administrated to induce dependence in mice. To induce the withdrawal syndrome, on the 4th day, naloxone was injected. Thirty minutes before naloxone administration, various doses of BSO (250, 500 mg/kg) and OPO (150, 300 mg/kg) were given as active treatments, along with saline and clonidine, to 6 groups. The data obtained were compared to those from other groups that received clonidine and saline separately (n=8). The levels of excitability, anxiety-like behavior, and pain threshold were assessed using the open field test, elevated plus maze (EPM), and hot plate tests. Findings: Clonidine and both studied doses of BSO significantly increased the presence of mice in the light arm of the EPM ( Conclusion: The present results revealed that the administration of BSO is effective in relieving the manifestations of morphine withdrawal syndrome, including anxiety, irritability, and motor activity, in a manner comparable to clonidine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.